Advice from CSL - From the Immunisation Section, Department of Health
Following the notification of several injection site adverse events, including cellulitis and/or abscess in patients and after discussion with the TGA, NSW Health and ACT Health, Merck Sharp & Dohme (MSD), as a precautionary measure has advised immunisation providers in NSW and the ACT that Pneumovax 23 (Batch No 3336; Expiry 22 June 2011) should not be administered. This stock will be collected through a process established and communicated to the immunisation providers by MSD.
Following receipt of the adverse event reports, an immediate investigation into the manufacturing process was commenced and an initial investigation has not revealed any adverse quality issues related to this batch. Further investigation is currently ongoing.
Please note that this batch was only distributed in NSW and the ACT.
Note: All enquiries regarding this information should be referred to CSL.
phone +613 9389 1956 | fax +613 9389 1874 | www.cslbiotherapies.com.au
